References
  1. Demlová R, Turjap M, Peš O, Kostolanská K, Juřica J. Therapeutic Drug Monitoring of Sunitinib in Gastrointestinal Stromal Tumors and Metastatic Renal Cell Carcinoma in Adults-A Review. Ther Drug Monit. 2020;42(1):20-32. doi:10.1097/FTD.0000000000000663. PMID: 31259881.
  2. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66(2):357-371. doi:10.1007/s00280-009-1170-y. PMID: 19967539.
  3. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25-35. doi:10.1200/JCO.2005.02.2194
  4. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-337. PMID: 12538485.
  5. Krishna VM, Noronha V, Prabhash K, et al. Sunitinib in metastatic renal cell carcimoma: a single-center experience. Indian J Cancer. 2013;50(3):268-273. doi:10.4103/0019-509X.118725. PMID: 24061470
  6. Gurjar M, Mehta P, Sharma J, Patil S, Kulkarni P, Patil A, Nookala KM, Joshi A, Gota V. An HPLC method for simultaneous quantification of sunitinib and its active metabolite, SU12662, using hydrophilic interaction chromatography principle. Bioanalysis. 2020;12:75-85. 10.4155/bio-2019-0188.
  7. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026. PMID: 19097774
  8. Lee JL, Kim MK, Park I, et al. Randomized phase II trial of Sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26:2300-2305.
  9. Noda S, Otsuji T, Baba M, et al. Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. Clin Genitourin Cancer. 2015;13(4):350-358. doi:10.1016/j.clgc.2015.01.007. PMID: 25701374.
  10. Uemura H, Shinohara N, Yuasa T, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol. 2010;40(3):194-202. doi:10.1093/jjco/hyp146. PMID: 19897852.
  11. Sehdev S. Sunitinib toxicity management - a practical approach. Can Urol Assoc J. 2016;10(11-12Suppl7):S248-S251. doi:10.5489/cuaj.4296
Figure Legends:Figure 1: (A) ROC curve of TTL of sunitinib for the prediction of grade ≥ 3 toxicity in all patients. (B) ROC curve of TTL of sunitinib for the prediction of responders in all patients. (C) Kaplan-Meier survival curves illustrating the progression-free survival based on TTL in all patients. Figure 2: (A) ROC curve of toxicity and TTL of sunitinib for the prediction of grade ≥ 3 toxicity in patients treated with 2/1 regimen. (B) ROC curve of TTL of sunitinib for the prediction of responders in patients treated with 2/1 regimen. (C) Kaplan-Meier survival curves illustrating the PFS based on TTL in patients treated with 2/1 regimen.
Supplementary Figure 1: Patient flow diagram
Supplementary Figure 2: Box and whisker plots showing trough levels of sunitinib, SU12662 and total sunitinib at steady state (N=60). The samples for sunitinib and SU12662 analysis was collected between days 10 to 14 in the first cycle of treatment. Supplementary Figure 3: Waterfall plot of best response in tumour size from baseline is shown. 8/12 (66.66%) patients who had TTL of sunitinib < 60 ng/mL had PD whereas 4/12 (33.33%) patients had SD. Among 18 patients who achieved TTL ≥ 82.3 ng/ml, 2 (11.11%) had PD, 13 (72.22%) patients had SD and three (16.66%) patients had PR. Out of 16 patients who had TTL of sunitinib in range of 60.75-82.3 ng/mL, one (6.25%) patient had PD, fourteen (87.5%) patients had SD while one patient (6.25%) had PR.